Copyright Reports & Markets. All rights reserved.

Global Alpha 1 Antitrypsin Deficiency Treatment Market Research Report 2019

Request for Sample of this report
Buy now

Table of Contents

    Executive Summary

      1 Alpha 1 Antitrypsin Deficiency Treatment Market Overview

      • 1.1 Product Overview and Scope of Alpha 1 Antitrypsin Deficiency Treatment
      • 1.2 Alpha 1 Antitrypsin Deficiency Treatment Segment by Type
        • 1.2.1 Global Alpha 1 Antitrypsin Deficiency Treatment Production Growth Rate Comparison by Type (2014-2025)
        • 1.2.2 Augmentation Therapy
        • 1.2.3 Bronchodilators
        • 1.2.4 Corticosteroids
        • 1.2.5 Oxygen Therapy
      • 1.3 Alpha 1 Antitrypsin Deficiency Treatment Segment by Application
        • 1.3.1 Alpha 1 Antitrypsin Deficiency Treatment Consumption Comparison by Application (2014-2025)
        • 1.3.2 Hospitals
        • 1.3.3 Specialty Clinics
        • 1.3.4 Pharmacies
      • 1.4 Global Alpha 1 Antitrypsin Deficiency Treatment Market by Region
        • 1.4.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Region
        • 1.4.2 North America Status and Prospect (2014-2025)
        • 1.4.3 Europe Status and Prospect (2014-2025)
        • 1.4.4 China Status and Prospect (2014-2025)
        • 1.4.5 Japan Status and Prospect (2014-2025)
      • 1.5 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size
        • 1.5.1 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue (2014-2025)
        • 1.5.2 Global Alpha 1 Antitrypsin Deficiency Treatment Production (2014-2025)

      2 Global Alpha 1 Antitrypsin Deficiency Treatment Market Competition by Manufacturers

      • 2.1 Global Alpha 1 Antitrypsin Deficiency Treatment Production Market Share by Manufacturers (2014-2019)
      • 2.2 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Manufacturers (2014-2019)
      • 2.3 Global Alpha 1 Antitrypsin Deficiency Treatment Average Price by Manufacturers (2014-2019)
      • 2.4 Manufacturers Alpha 1 Antitrypsin Deficiency Treatment Production Sites, Area Served, Product Types
      • 2.5 Alpha 1 Antitrypsin Deficiency Treatment Market Competitive Situation and Trends
        • 2.5.1 Alpha 1 Antitrypsin Deficiency Treatment Market Concentration Rate
        • 2.5.2 Alpha 1 Antitrypsin Deficiency Treatment Market Share of Top 3 and Top 5 Manufacturers
        • 2.5.3 Mergers & Acquisitions, Expansion

      3 Global Alpha 1 Antitrypsin Deficiency Treatment Production Market Share by Regions

      • 3.1 Global Alpha 1 Antitrypsin Deficiency Treatment Production Market Share by Regions
      • 3.2 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Regions (2014-2019)
      • 3.3 Global Alpha 1 Antitrypsin Deficiency Treatment Production, Revenue, Price and Gross Margin (2014-2019)
      • 3.4 North America Alpha 1 Antitrypsin Deficiency Treatment Production
        • 3.4.1 North America Alpha 1 Antitrypsin Deficiency Treatment Production Growth Rate (2014-2019)
        • 3.4.2 North America Alpha 1 Antitrypsin Deficiency Treatment Production, Revenue, Price and Gross Margin (2014-2019)
      • 3.5 Europe Alpha 1 Antitrypsin Deficiency Treatment Production
        • 3.5.1 Europe Alpha 1 Antitrypsin Deficiency Treatment Production Growth Rate (2014-2019)
        • 3.5.2 Europe Alpha 1 Antitrypsin Deficiency Treatment Production, Revenue, Price and Gross Margin (2014-2019)
      • 3.6 China Alpha 1 Antitrypsin Deficiency Treatment Production (2014-2019)
        • 3.6.1 China Alpha 1 Antitrypsin Deficiency Treatment Production Growth Rate (2014-2019)
        • 3.6.2 China Alpha 1 Antitrypsin Deficiency Treatment Production, Revenue, Price and Gross Margin (2014-2019)
      • 3.7 Japan Alpha 1 Antitrypsin Deficiency Treatment Production (2014-2019)
        • 3.7.1 Japan Alpha 1 Antitrypsin Deficiency Treatment Production Growth Rate (2014-2019)
        • 3.7.2 Japan Alpha 1 Antitrypsin Deficiency Treatment Production, Revenue, Price and Gross Margin (2014-2019)

      4 Global Alpha 1 Antitrypsin Deficiency Treatment Consumption by Regions

      • 4.1 Global Alpha 1 Antitrypsin Deficiency Treatment Consumption by Regions
      • 4.2 North America Alpha 1 Antitrypsin Deficiency Treatment Consumption (2014-2019)
      • 4.3 Europe Alpha 1 Antitrypsin Deficiency Treatment Consumption (2014-2019)
      • 4.4 China Alpha 1 Antitrypsin Deficiency Treatment Consumption (2014-2019)
      • 4.5 Japan Alpha 1 Antitrypsin Deficiency Treatment Consumption (2014-2019)

      5 Global Alpha 1 Antitrypsin Deficiency Treatment Production, Revenue, Price Trend by Type

      • 5.1 Global Alpha 1 Antitrypsin Deficiency Treatment Production Market Share by Type (2014-2019)
      • 5.2 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Type (2014-2019)
      • 5.3 Global Alpha 1 Antitrypsin Deficiency Treatment Price by Type (2014-2019)
      • 5.4 Global Alpha 1 Antitrypsin Deficiency Treatment Production Growth by Type (2014-2019)

      6 Global Alpha 1 Antitrypsin Deficiency Treatment Market Analysis by Applications

      • 6.1 Global Alpha 1 Antitrypsin Deficiency Treatment Consumption Market Share by Application (2014-2019)
      • 6.2 Global Alpha 1 Antitrypsin Deficiency Treatment Consumption Growth Rate by Application (2014-2019)

      7 Company Profiles and Key Figures in Alpha 1 Antitrypsin Deficiency Treatment Business

      • 7.1 Pfizer
        • 7.1.1 Pfizer Alpha 1 Antitrypsin Deficiency Treatment Production Sites and Area Served
        • 7.1.2 Alpha 1 Antitrypsin Deficiency Treatment Product Introduction, Application and Specification
        • 7.1.3 Pfizer Alpha 1 Antitrypsin Deficiency Treatment Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.1.4 Main Business and Markets Served
      • 7.2 Baxter
        • 7.2.1 Baxter Alpha 1 Antitrypsin Deficiency Treatment Production Sites and Area Served
        • 7.2.2 Alpha 1 Antitrypsin Deficiency Treatment Product Introduction, Application and Specification
        • 7.2.3 Baxter Alpha 1 Antitrypsin Deficiency Treatment Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.2.4 Main Business and Markets Served
      • 7.3 AstraZeneca
        • 7.3.1 AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Production Sites and Area Served
        • 7.3.2 Alpha 1 Antitrypsin Deficiency Treatment Product Introduction, Application and Specification
        • 7.3.3 AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.3.4 Main Business and Markets Served
      • 7.4 Grifols
        • 7.4.1 Grifols Alpha 1 Antitrypsin Deficiency Treatment Production Sites and Area Served
        • 7.4.2 Alpha 1 Antitrypsin Deficiency Treatment Product Introduction, Application and Specification
        • 7.4.3 Grifols Alpha 1 Antitrypsin Deficiency Treatment Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.4.4 Main Business and Markets Served
      • 7.5 Teva Pharmaceutical Industries
        • 7.5.1 Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Production Sites and Area Served
        • 7.5.2 Alpha 1 Antitrypsin Deficiency Treatment Product Introduction, Application and Specification
        • 7.5.3 Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.5.4 Main Business and Markets Served
      • 7.6 Boehringer Ingelheim
        • 7.6.1 Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Production Sites and Area Served
        • 7.6.2 Alpha 1 Antitrypsin Deficiency Treatment Product Introduction, Application and Specification
        • 7.6.3 Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.6.4 Main Business and Markets Served
      • 7.7 Kamada Ltd
        • 7.7.1 Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Production Sites and Area Served
        • 7.7.2 Alpha 1 Antitrypsin Deficiency Treatment Product Introduction, Application and Specification
        • 7.7.3 Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.7.4 Main Business and Markets Served
      • 7.8 GlaxoSmithKline
        • 7.8.1 GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Production Sites and Area Served
        • 7.8.2 Alpha 1 Antitrypsin Deficiency Treatment Product Introduction, Application and Specification
        • 7.8.3 GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.8.4 Main Business and Markets Served
      • 7.9 CSL Behring
        • 7.9.1 CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Production Sites and Area Served
        • 7.9.2 Alpha 1 Antitrypsin Deficiency Treatment Product Introduction, Application and Specification
        • 7.9.3 CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.9.4 Main Business and Markets Served
      • 7.10 Shire
        • 7.10.1 Shire Alpha 1 Antitrypsin Deficiency Treatment Production Sites and Area Served
        • 7.10.2 Alpha 1 Antitrypsin Deficiency Treatment Product Introduction, Application and Specification
        • 7.10.3 Shire Alpha 1 Antitrypsin Deficiency Treatment Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.10.4 Main Business and Markets Served
      • 7.11 LFB Biomedicaments
      • 7.12 Abeona Therapeutics
      • 7.13 Biogen
      • 7.14 Applied Genetic Technologies
      • 7.15 Baxalta
      • 7.16 Arrowhead Research Corporation
      • 7.17 ProBioGen
      • 7.18 Chiesi Pharmaceuticals
      • 7.19 Curaxys
      • 7.20 ProMetic Life Sciences

      8 Alpha 1 Antitrypsin Deficiency Treatment Manufacturing Cost Analysis

      • 8.1 Alpha 1 Antitrypsin Deficiency Treatment Key Raw Materials Analysis
        • 8.1.1 Key Raw Materials
        • 8.1.2 Price Trend of Key Raw Materials
        • 8.1.3 Key Suppliers of Raw Materials
      • 8.2 Proportion of Manufacturing Cost Structure
      • 8.3 Manufacturing Process Analysis of Alpha 1 Antitrypsin Deficiency Treatment
      • 8.4 Alpha 1 Antitrypsin Deficiency Treatment Industrial Chain Analysis

      9 Marketing Channel, Distributors and Customers

      • 9.1 Marketing Channel
        • 9.1.1 Direct Marketing
        • 9.1.2 Indirect Marketing
      • 9.2 Alpha 1 Antitrypsin Deficiency Treatment Distributors List
      • 9.3 Alpha 1 Antitrypsin Deficiency Treatment Customers

      10 Market Dynamics

      • 10.1 Market Trends
      • 10.2 Opportunities
      • 10.3 Market Drivers
      • 10.4 Challenges
      • 10.5 Influence Factors

      11 Global Alpha 1 Antitrypsin Deficiency Treatment Market Forecast

      • 11.1 Global Alpha 1 Antitrypsin Deficiency Treatment Production, Revenue Forecast
        • 11.1.1 Global Alpha 1 Antitrypsin Deficiency Treatment Production Growth Rate Forecast (2019-2025)
        • 11.1.2 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate Forecast (2019-2025)
        • 11.1.3 Global Alpha 1 Antitrypsin Deficiency Treatment Price and Trend Forecast (2019-2025)
      • 11.2 Global Alpha 1 Antitrypsin Deficiency Treatment Production Forecast by Regions (2019-2025)
        • 11.2.1 North America Alpha 1 Antitrypsin Deficiency Treatment Production, Revenue Forecast (2019-2025)
        • 11.2.2 Europe Alpha 1 Antitrypsin Deficiency Treatment Production, Revenue Forecast (2019-2025)
        • 11.2.3 China Alpha 1 Antitrypsin Deficiency Treatment Production, Revenue Forecast (2019-2025)
        • 11.2.4 Japan Alpha 1 Antitrypsin Deficiency Treatment Production, Revenue Forecast (2019-2025)
      • 11.3 Global Alpha 1 Antitrypsin Deficiency Treatment Consumption Forecast by Regions (2019-2025)
        • 11.3.1 North America Alpha 1 Antitrypsin Deficiency Treatment Consumption Forecast (2019-2025)
        • 11.3.2 Europe Alpha 1 Antitrypsin Deficiency Treatment Consumption Forecast (2019-2025)
        • 11.3.3 China Alpha 1 Antitrypsin Deficiency Treatment Consumption Forecast (2019-2025)
        • 11.3.4 Japan Alpha 1 Antitrypsin Deficiency Treatment Consumption Forecast (2019-2025)
      • 11.4 Global Alpha 1 Antitrypsin Deficiency Treatment Production, Revenue and Price Forecast by Type (2019-2025)
      • 11.5 Global Alpha 1 Antitrypsin Deficiency Treatment Consumption Forecast by Application (2019-2025)

      12 Research Findings and Conclusion

        13 Methodology and Data Source

        • 13.1 Methodology/Research Approach
          • 13.1.1 Research Programs/Design
          • 13.1.2 Market Size Estimation
          • 13.1.3 Market Breakdown and Data Triangulation
        • 13.2 Data Source
          • 13.2.1 Secondary Sources
          • 13.2.2 Primary Sources
        • 13.3 Author List

        Severe deficiency of alpha-1 antitrypsin (AAT) can cause early-onset emphysema and several liver diseases, including cirrhosis, neonatal hepatitis and hepatocellular carcinoma.
        The discovery of the structure and function of the AAT protein and the subsequent isolation and purification thereof have made possible alternative therapies aimed at preventing the progression of related pulmonary diseases (so-called "additional therapies"). The isolation of this gene and the advancement of gene therapy have further increased the possibility of specific treatment. Most specific treatments for AAT deficiency aim to increase plasma AAT levels (and thus elevated AAT concentrations in the interstitial lung) above the protection threshold. Other experimental therapeutic approaches attempt to interfere with the production of abnormal AAT proteins or to inhibit the polymerization of abnormal AAT proteins and to promote the secretion of AAT from hepatocytes. For patients with end-stage lung disease or liver disease, organ transplantation is another treatment option.
        Currently, the most direct and effective way to increase AAT levels in plasma and interstitial lung is by intravenous infusion of pooled alpha-1 antitrypsin (pAAT).

        The global Alpha 1 Antitrypsin Deficiency Treatment market is valued at 1190 million US$ in 2018 is expected to reach 2560 million US$ by the end of 2025, growing at a CAGR of 10.1% during 2019-2025.
        This report focuses on Alpha 1 Antitrypsin Deficiency Treatment volume and value at global level, regional level and company level. From a global perspective, this report represents overall Alpha 1 Antitrypsin Deficiency Treatment market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
        At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

        The following manufacturers are covered:
        Pfizer
        Baxter
        AstraZeneca
        Grifols
        Teva Pharmaceutical Industries
        Boehringer Ingelheim
        Kamada Ltd
        GlaxoSmithKline
        CSL Behring
        Shire
        LFB Biomedicaments
        Abeona Therapeutics
        Biogen
        Applied Genetic Technologies
        Baxalta
        Arrowhead Research Corporation
        ProBioGen
        Chiesi Pharmaceuticals
        Curaxys
        ProMetic Life Sciences

        Segment by Regions
        North America
        Europe
        China
        Japan

        Segment by Type
        Augmentation Therapy
        Bronchodilators
        Corticosteroids
        Oxygen Therapy

        Segment by Application
        Hospitals
        Specialty Clinics
        Pharmacies

        Buy now